Continuous infusion interleukin-2 and antihistamines in melanoma: A retrospective review showing activity of this combination

Cancer Biotherapy and Radiopharmaceuticals

Volumn 19, Issue 6, 2004, Pages 754-757

  Evangelista Dean, Maria ^a   Khan, Nawazish ^a   Quan Jr , Walter ^b  

^a EAST CAROLINA UNIVERSITY   (United States)

^b MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

Cimetidine; Interleukin 2; Lymphokine activated killer (LAK) cells; Melanoma; Ranitidine

Indexed keywords

ANTIHISTAMINIC AGENT; CIMETIDINE; FAMOTIDINE; INTERLEUKIN 2; RANITIDINE;

ANTINEOPLASTIC ACTIVITY; CONTINUOUS INFUSION; GASTROINTESTINAL TOXICITY; HUMAN; LYMPHOKINE ACTIVATED KILLER CELL; MEDLINE; MELANOMA; MONOTHERAPY; NATURAL KILLER CELL; PRIORITY JOURNAL; PROPHYLAXIS; RETROSPECTIVE STUDY; REVIEW; SYSTEMATIC REVIEW; TUMOR ASSOCIATED LEUKOCYTE;

ANTINEOPLASTIC AGENTS; DRUG THERAPY, COMBINATION; HISTAMINE H1 ANTAGONISTS; HUMANS; INFUSIONS, INTRAVENOUS; INTERLEUKIN-2; MELANOMA; RETROSPECTIVE STUDIES; SKIN NEOPLASMS;

EID: 14044262290     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2004.19.754     Document Type: Review

References (22)

1. Atkins M, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105.
2. Dillman RO, Church C, Oldham RK, et al. Inpatient continuous infusion interleukin-2 in 788 patients with cancer. The National Biotherapy Study Group experience. Cancer 1993;71:2358.
3. Papa MZ, Mule JJ, Rosenberg SA. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: Successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three distinct histologic types. Cancer Res 1986;46:4973.
4. Hawkins MJ. Interleukin-2 antitumor and effector cell responses. Semin Oncol 1993;20(Suppl. 9):52.
5. Hellstrand K, Brune M, Naredi P, et al. Histamine: A novel approach to cancer immunotherapy. Cancer Invest 2000;18:347.
6. Hellstrand K, Asea A, Dahlgren C, et al. Histaminergic regulation of NK-cells: Role of monocyte-derived, reactive oxygen metabolites. J Immunol 1994;153:4940.
7. Hansson M, Hermodsson S, Brune M, et al. Histamine protects T cells and NK cells against oxidative stress. J Interferon Cytokine Res 1999;19:1135.
8. Agarwala SS, Glaspy J, O'Day SJ, et al. Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol 2002;20:125.
9. Kikuchi Y, Oomori K, Kizawa I, et al. The effect of cimetidine on natural killer activity of peripheral blood lymphocytes of patients with ovarian carcinoma. Japn J Clin Oncol 1985;15:377.
10. Flodgren P, Sjogren HO. Influence in vitro on NK and K cell activities by cimetidine and indomethacin with and without simultaneous exposure to interferon. Cancer Immun Immunother 1985;19:28.
11. Allen JI, Syropoulos HJ, Grant B, et al. Cimetidine modulates natural killer cell function of patients with chronic lymphocytic leukemia. J Lab Clin Med 1987;109:396.
12. Mertens WC, Bramwell VH, Banerjee D, et al. Sustained indomethacin and ranitidine with intermittent continuous infusion interleukin-2 in advanced malignant melanoma: A phase II study. Clin Oncol (Royal College of Radiologists) 1993;5:107.
13. Dutcher JP, Gaynor ER, Boldt DH, et al. A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma. J Clin Oncol 1991;9:641.
14. Dillman RO, Oldham RK, Tauer KW, et al. Continuous infusion interleukin-2 and lymphokine-activated killer cells for advanced cancer: A National Biotherapy Study Group trial. J Clin Oncol 1991;9:1233.
15. Dillman RO, Oldham RK, Barth NM, et al. Continuous infusion interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma. A National Biotherapy Study Group trial. Cancer 1991;68:1.
16. Gaynor ER, Weiss GR, Margolin KA, et al. Phase I study of high-dose continuous infusion recombinant interleukin-2 and autologous lymphokine-activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinoma. J Natl Cancer Inst 1990;82:1397.
17. Bar MH, Sznol M, Atkins MB, et al. Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells. J Clin Oncol 1990;8:1138.
18. Kradin RL, Lazarus DS, Dubinett SM, et al. Tumor-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer. Lancet 1989;1:577.
19. Dillman RO, The clinical experience with interleukin-2 in cancer therapy. Cancer Biother Radiopharm 1994; 9:183.
20. Dillman RO: What to do with IL-2? Cancer Biother Radiopharm 1999;14:423.
21. Quan Jr W, Vinogradov M, Brick W, et al. Repeated cycles with 72-hour continuous infusion interleukin-2 in kidney cancer and melanoma. J Immunother 2003; 26:522.
22. Quan Jr W, Taylor WC, Brick W, et al. Continuous infusion followed by pulse interleukin-2 in melanoma and kidney cancer. J Immunother 2003;26:S22.